Ketorolac at Lower Doses for Analgesic Pain Control in ICU: A Pilot Feasibility Study

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Pain Management
Interventions
DRUG

Ketorolac

Ketorolac 15 mg IV q6h for a maximum of 3 days total or discharge from ICU (whichever comes first). The ketorolac will be diluted in a 0.9% normal saline 10 mL syringe.

DRUG

Placebo

Matching placebo IV q6h for a maximum of 3 days total or discharge from ICU (whichever comes first). The matching placebo will be diluted in a 0.9% normal saline 10 mL syringe.

Trial Locations (1)

T6G 2B7

RECRUITING

University of Alberta Hospital, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

NCT06819956 - Ketorolac at Lower Doses for Analgesic Pain Control in ICU: A Pilot Feasibility Study | Biotech Hunter | Biotech Hunter